|
| Author, years | N | Age, range (average) | Sex (M/F) | ASA (N) | Fluid A | Fluid B | Fluid C | Operation | Primary outcome/primary end point |
|
| Ando et al. [18], 2008 | 21 | 67 (60, 70) | 12/9 | I/II (9/12) | Acetate Ringer | HES70/0.5 (Hespander) | — | Major abdominal surgery | Urinary microalbumin/creatinine ratio |
| Chaudhary et al. [19], 2008 | 60 | 41 ± 11.06 | — | I/II | LRS 2 mL/kg | LRS 12 mL/kg | 4.5% hetastarch 12 mL/kg | Open cholecystectomy | PONV at 24 hours (VAS) |
| Demir et al. [20], 2018 | 36 | 42.72 ± 13.25 | 25/11 | II/III/IV (21/8/7) | 6% HES130/0.4 (Voluven) | 4% gelatin (Gelofusine) | — | Living donor liver transplant | Renal function (Cr, BUN, and GFR) |
| Deng et al. [21], 2017 | 36 | 40–80 | 20/16 | I/II | LRS | 4% gelatin (Gelofusine) | 4.5% NaCl in 7.6% HES40 | Laparoscopic colonic surgery | Mucosal blood flow (Pg-aCO2) |
| Feldheiser et al. [15], 2013 | 48 | 52.5 (45.5, 59) | — | I/II/III (4/24/20) | Jonosteril | 6% HES130/0.4 (Volulyte) | — | Cytoreductive surgery | Amount of fluid |
| Ghodraty et al. [22], 2017 | 91 | 53.2 ± 12.3 | 60/31 | II/III (38/53) | LRS | 6% HES130/0.4 (Voluven) | — | GI surgery | Presence of bowel function |
| Hung et al. [23], 2014 | 80 | 48 ± 10.7 | 48/32 | — | LRS | 6% HES130/0.4 (Voluven) | — | Major abdominal surgery | Thromboelastogram |
| Ickx et al. [24], 2003 | 40 | 62 (47–72) | 39/1 | II/III | 6% HES130/0.4 (Voluven) | 6% HES200/0.5 (HAES-steril) | — | Major abdominal surgery | Plasma substitution effect (CO, RVEDV) |
| Jin et al. [25], 2010 | 42 | 49 ± 10 | 15/27 | I/II | LRS | 6% HES130/0.4 (Voluven) | 4% gelatin (Gelofusine) | Gastrectomy | Thromboelastogram |
| Joosten et al. [17], 2018 | 160 | 62 (48–70) | 96/84 | II/III (93/67) | Plasmalyte | 6% HES130/0.4 (Volulyte) | — | Major abdominal surgery | Postoperative complication at day 2 |
| Kammerer et al. [26], 2018 | 100 | 70 (61–75) | 81/19 | I/II/III/IV (6/38/63/2) | 5% human albumin | 6% HES130/0.4 (Voluven) | — | Cystectomy | Serum cystatin C ratio (preoperative/ postoperative day 90) |
| Kancir et al. [27], 2015 | 36 | 64 (4.8) | — | — | NSS | 6% HES130/0.4 (Voluven) | — | Radical cystectomy | Urine NGAL |
| Khajavi et al. [28], 2008 | 54 | 40 ± 14 | — | — | NSS | LRS | — | Living donor kidney transplant | Serum potassium and pH |
| Kim et al. [29], 2013 | 60 | 46 ± 12 | 38/22 | III/IV | NSS | Plasmalyte | — | Living donor kidney transplant | Renal function |
| Lavu et al. [30], 2014 | 259 | 68.3 (25–91) | 39%/46% | III (167) | LRS | 3% sodium chloride | — | Pancreaticoduodenectomy | Postoperative complication |
| Liang et al. [31], 2010 | 35 | 57 ± 8 | 15/20 | I/II | 6% HES130/0.4 (Voluven) | 6% HES200/0.5 (HAES-steril) | — | Laparoscopy-assisted radical colectomy | Thromboelastogram |
| Loffel et al. [32], 2016 | 44 | 71.5 (33–82) | 30/14 | II/III (28/16) | Ringer maleate | Chloride-depleted glucose solution 5% (G5K) | — | Cystectomy | First defecation |
| Mahmood et al. [33], 2007 | 62 | 72 (7) | 50/12 | — | 6% HES 200/0.62 (Elohes) | 6% HES130/0.4 (Voluven) | 4% gelatin (Gelofusine) | Open AAA repair | Splanchnic perfusion (gastric pH) |
| Mahmood et al. [34], 2009 | 62 | 72 (7) | 50/12 | — | 6% HES 200/0.62 (Elohes) | 6% HES130/0.4 (Voluven) | 4% gelatin (Gelofusine) | Open AAA repair | Renal function (Cr, GFR) |
| Marik et al. [35], 1997 | 30 | — | — | — | LRS | HES670/0.75 (hetastarch) | — | Open AAA repair | Maximal change of gastric pH |
| Mishra et al. [36], 2017 | 100 | 39.6 ± 11.54 | 28/72 | I/II (81/19) | NSS | 5% Dextrose | — | Laparoscopic cholecystectomy | Incidence of PONV |
| Modi et al. [37], 2012 | 72 | 18–62 | - | — | NSS | LRS | — | Living donor kidney transplant | Acidosis, potassium |
| Mukhtar et al. [38], 2009 | 40 | 51 ± 6 | 35/5 | — | 5% human albumin | 6% HES130/0.4 (Voluven) | — | Living donor liver transplant | Creatinine clearance at 24 hours |
| O’Malley et al. [39], 2005 | 51 | 44 ± 13 | 32/19 | — | NSS | LRS | — | Kidney transplant | Cr at postoperative day 3 |
| Potura et al. [40], 2015 | 148 | 56 ± 13 | 95/53 | — | NSS | Elomel-Isoton | — | Cadaveric kidney transplant | Perioperative hyperkalemia |
| Ragaller et al. [41], 2000 | 29 | 68.4 ± 8.5 | 26/3 | I/II/III | 6% HES200/0.5 + 0.9%NaCl | 6% HES200/0.5 + 7.2%NaCl | — | Open AAA repair | Amount of fluid to restore PCWP |
| Rao et al. [42], 2017 | 112 | 19–60 | — | I/II | LRS | 5% dextrose | — | Laparoscopic cholecystectomy | Incidence of PONV |
| Rasmussen et al. [43], 2014 | 33 | 64.1 (7.9) | 26/7 | I/II/III | LRS | Dextran 70 | — | Cystectomy | Thromboelastogram |
| Rasmussen et al. [44], 2015 | 37 | 68 (61.9–74.3) | 27/10 | I/II/III | LRS | 5% human albumin | — | Cystectomy | Thromboelastogram |
| Rasmussen et al. [45], 2016 | 39 | 69 (66–72) | 25/14 | I/II/III | LRS | 6% HES130/0.4 (Voluven) | — | Cystectomy | Thromboelastogram |
| Rittoo et al. [46], 2002 | 22 | 70.6 ± 2.18 | 15/7 | — | 4% gelatin (Gelofusine) | 6% HES200/0.62 (Elohes) | — | Open AAA repair | Splanchnic perfusion (gastric pH) |
| Rittoo et al. [47], 2005 | 40 | 71.2 (6.7) | 30/10 | — | 4% gelatin (Gelofusine) | 6% HES200/0.62 (Elohes) | — | Open AAA repair | Inflammatory marker |
| Sander et al. [48], 2003 | 56 | 45 ± 15 | — | I/II/III (16/36/4) | 6% HES130/0.4 (Voluven) | 6% HES200/0.5 | — | Major gynecological surgery | Hemodynamic maintenance |
| Senagore et al. [49], 2009 | 64 | — | — | I/II/III | Standard-LR | Goal-directed LR | Goal-directed hetastarch | Laparoscopic colonic surgery | Length of hospital stay |
| Szturz et al. [50], 2014 | 115 | 61 (27–87) | 83/32 | I/II/III/IV | LRS | 6% HES130/0.4 (Voluven) | — | Major urological surgery | Efficiency of volume expansion |
| Vogt et al. [51], 1999 | 48 | 65 (7.1) | — | I/II/III (4/33/13) | 5% human albumin | 6% HES200/0.5 | — | Major urological surgery | Hemodynamic stability effect |
| Waters et al. [52], 2001 | 66 | 69.8 ± 8.7 | — | I-IV (III) | NSS | LRS | — | Open AAA repair | Change in base excess |
| Weinberg et al. [53], 2015 | 60 | 63 (38–85) | 36/24 | I/II/III (1/26/33) | Hartmann solution | Plasmalyte | — | Major liver resection | Immediate postoperative base excess |
| Weinberg et al. [54], 2017 | 49 | 49 (26–67) | 33/16 | — | NSS | Plasmalyte | — | Cadaveric kidney transplant | Postoperative hyperkalemia 48 hours |
| Yates et al. [16], 2014 | 202 | 72 (56–88) | 117/85 | I/II/III/IV (20/119/62/1) | Hartmann solution | 6% HES130/0.4 (Volulyte) | — | Colorectal surgery | GI morbidity at postoperative day 5 |
| Yuan et al. [55], 2008 | 127 | 56.1 ± 15.3 | 69/58 | — | NSS | 20% human albumin | — | Major abdominal surgery | Albumin level |
| Zhang et al. [56], 2012 | 60 | 56.7 ± 6.9 | 42/18 | I/II (32/28) | Restricted-LR | Goal-directed LR | Goal-directed HES130/0.4 | GI surgery | Length of hospital stay |
| Zhu et al. [57], 2018 | 71 | 73 ± 7 | 46/34 | I/II | LRS | 4% gelatin (Gelofusine) | 4.5% NaCl in 7.6% HES40 | Laparoscopic colonic surgery | Splanchnic perfusion (gastric pH) |
|
